gastroesophageal adenocarcinoma (Cancer)
Information
- Disease name
- gastroesophageal adenocarcinoma
- Disease ID
- DOID:0080375
- Description
- "A gastroesophageal cancer that has_material_basis_in abnormally proliferating cells, derives_from epithelial cells, which originate in glandular tissue." [url:https\://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827797]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04021108 | Active, not recruiting | Phase 2 | Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) | July 22, 2019 | April 2026 |
| NCT01045421 | Completed | Phase 1/Phase 2 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies | February 2010 | April 2014 |
| NCT00073502 | Completed | Phase 2 | Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer | October 2003 | October 2003 |
| NCT01757171 | Completed | Phase 2 | Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma | December 2012 | June 2017 |
| NCT03639714 | Completed | Phase 1/Phase 2 | A Study of a Personalized Neoantigen Cancer Vaccine | February 13, 2019 | November 10, 2022 |
| NCT03794128 | Completed | A Study of Personalized Neoantigen Cancer Vaccines | July 25, 2018 | May 26, 2020 | |
| NCT06445972 | Not yet recruiting | Phase 1/Phase 2 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | July 1, 2024 | October 27, 2028 |
| NCT05733689 | Not yet recruiting | Phase 1 | Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) | February 2025 | February 2026 |
| NCT05986227 | Not yet recruiting | Phase 1/Phase 2 | The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II): | August 1, 2023 | July 1, 2026 |
| NCT05977322 | Recruiting | Phase 1 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | October 6, 2023 | January 26, 2027 |
| NCT05152147 | Recruiting | Phase 3 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | December 2, 2021 | February 1, 2026 |
| NCT06043427 | Recruiting | Phase 2 | Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma | April 16, 2024 | June 30, 2026 |
| NCT05029882 | Recruiting | Phase 1 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | October 13, 2021 | November 23, 2025 |
| NCT04712721 | Recruiting | Early Phase 1 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. | October 14, 2021 | June 26, 2024 |
| NCT01182610 | Terminated | Phase 2 | Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma | April 2011 | March 2012 |
| NCT04602117 | Withdrawn | Phase 1 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | July 28, 2021 | November 17, 2021 |
- Disase is a (Disease Ontology)
- DOID:0080374
- Exact Synonym (Disease Ontology)
- gastric and esophageal adenocarcinoma
- Exact Synonym (Disease Ontology)
- gastro-esophageal adenocarcinoma